A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria:

• Have Crohn's disease (CD) or fistulizing Crohn's disease of at least 3 monthsduration (defined as a minimum of 12 weeks), with colitis, ileitis, or ileocolitis,confirmed at any time in the past by radiography, histology, and/or endoscopy

• Have moderate to severe CD as assessed by CDAI, stool frequency (SF), and abdominalpain (AP) scores, and Simple Endoscopic Score for Crohn's Disease (SES-CD)

• Have screening laboratory test results within the protocol specified parameters

• A female participant of childbearing potential must have a negative urine pregnancytest result at screening and baseline

• Demonstrated intolerance or inadequate response to conventional or to biologictherapy for CD

Exclusion Criteria:

• Current diagnosis of ulcerative colitis or indeterminate colitis

• Has complications of Crohn's disease, such as symptomatic strictures or stenoses,short gut syndrome, or any other manifestation

• Unstable doses of concomitant Crohn's disease therapy

• Receipt of Crohn's disease approved biologic agents, investigational agents, orprocedures outside of permitted timeframe as specified in the protocol

• Any medical contraindications preventing study participation